Hans Schambye

Hans Schambye

Chairman of the Board

Hans Schambye is a seasoned biotech entrepreneur with extensive experience in drug discovery and development. He is the co-founder and CEO of Galecto Biotech AB. Previously, Hans was the Chief Executive Officer of ReceptIcon from 2006 to 2009 and as the CEO of Gastrotech Pharma A/S from 2004 to 2006. Before joining Gastrotech, he was Director of Biology and Pharmacology and Head of Portfolio Management at Maxygen, a US biotech company. Hans has co-founded several biotech companies, including ProFound Pharma A/S, a Danish biotech company, which was acquired by Maxygen in 2000. Prior to this he had a successful research career at Stanford University and Copenhagen University within the field of receptor biology. Hans holds an MD from Odense University and a PhD in Medical Sciences from Copenhagen University.

Per Antonsson

Per Antonsson

Per has a background within pre-clinical research from Pharmacia & Upjohn and holds a PhD in experimental medicine from the University of Lund. He has over 15 years of experience as business advisor and investor and are currently Investment Manager at Almi Invest.

Morten Graugaard Døssing

Morten Graugaard Døssing

Prior to joining Novo, Morten was Director of Corporate Development at H. Lundbeck A/S where he was involved in M&A, corporate strategy, BD&L, portfolio management and equity investments. While at Lundbeck Morten successfully led the acquisition of orphan neurology company Chelsea Therapeutics for 658 USD m and was involved in a range of other deals including the 1.8 USD Bn alliance with Otsuka Pharmaceuticals as well as equity investments and spinouts. Before Lundbeck, Morten worked as commercial manager in technology transfer to commercialize and establish new companies in biotech and medtech. Earlier in his career, Morten co-led the life science consulting practice at a boutique advisory firm in Copenhagen focusing on business development and management consulting. Morten holds an MSc in Human Biology from the University of Copenhagen. Morten is Investment Director at Novo Seeds.

Tomas Eriksson

Tomas Eriksson

BSc Econ, is co-founder and CEO of A1M Pharma AB. The company develops novel pharmaceutical treatments based on alpha-1-microglobuin, an endogenous regulatory protein. He has extensive management and finance experience in early stage biotech companies over the past 8 years having previously spent over 15 years managing sales and marketing in international medical technology and diagnostics.

Martina Kvist Reimer

Martina Kvist Reimer

Martina Kvist Reimer is one of the founders of Red Glead Discovery, where she besides holding the position of Executive Vice President also is a board member. She has more than 15 years of experience in pharmaceutical research and biotech serving in various positions with AstraZeneca, and more recently as a CEO of Apoglyx AB. At AstraZeneca, she gathered broad experience of the drug discovery process and supported the development of small molecule candidates from preclinical to clinical phase. Expect for her business mind set and ability for conceptual and strategic thinking, she brings with her a passion for the cause of Merozyme. Martina received a Masters’ degree in biology from Ruhr-University Bochum in Germany and a PhD from Lund University, Sweden.

Karolina Rask

Karolina Rask

Karolina obtained her MSc degree in biomedical chemistry for Kalmar University in 2000. Her early career started off as a molecular biologist working at Rockefeller University in New York City where she did her master thesis. Currently she holds a position as Director Clinical Development at AstraZeneca in Göteborg Sweden. Her career has for the past 12 years been focused within clinical development in a number of positions in pharma, biotech and the CRO industry (in Novo Nordisk, Genmab, Mitsubishi Tanabe pharma etc.), having a global career spread between the US, UK, Sweden and Denmark. For about three years she ran as CEO a virtual biotech company called Thrombologic where Novo Seeds was an investor where she worked with re-positioning known compounds towards an orphan disease and severe sepsis.